Response of Resting Human Peripheral Blood Natural Killer Cells to Interleukin 2

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1984 Oct 1

PMID 6434688

Citations 183

Authors

G Trinchieri

S C Clark

J Seehra

L London

B Perussia

Affiliations

Soon will be listed here.

Abstract

The present study shows that recombinant interleukin 2 (IL-2) purified to homogeneity induces a rapid and potent enhancement of spontaneous cytotoxicity of human peripheral blood lymphocytes. The cells mediating cytotoxicity after 18-h treatment with IL-2 have surface markers of natural killer (NK) cells and are generated from the peripheral blood subset containing spontaneous cytotoxic cells. A parallel production of gamma interferon (IFN-gamma) is induced by recombinant IL-2 (rIL-2), and NK cells appear to be the major producer cells, whereas T cells are unable to produce IFN-gamma under these experimental conditions. However, the kinetics of the enhancement of cytotoxicity are faster than those of IFN-gamma production, and monoclonal anti-IFN-gamma antibodies do not suppress this effect, making it unlikely that the IFN-gamma produced is responsible for the enhancement. The enhancement of NK cell activity induced by rIL-2 precedes any proliferative response of the lymphocytes, which is instead observed in longer-term cultures of both NK and T cells.

Citing Articles

The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma.

Pathania A, Chava H, Chaturvedi N, Chava S, Byrareddy S, Coulter D Cell Death Dis. 2024; 15(6):428.

PMID: 38890285 PMC: 11189583. DOI: 10.1038/s41419-024-06791-7.

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.

Moynihan K, Kumar M, Sultan H, Pappas D, Park T, Chin S Cancer Discov. 2024; 14(7):1206-1225.

PMID: 38563906 PMC: 11215410. DOI: 10.1158/2159-8290.CD-23-1266.

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.

Arora J, Ayyappan S, Yin C, Smith B, Lemke-Miltner C, Wang Z Blood. 2024; 143(18):1816-1824.

PMID: 38457360 PMC: 11076912. DOI: 10.1182/blood.2023023370.

Osteoclasts and Probiotics Mediate Significant Expansion, Functional Activation and Supercharging in NK, γδ T, and CD3+ T Cells: Use in Cancer Immunotherapy.

Kaur K, Jewett A Cells. 2024; 13(3.

PMID: 38334605 PMC: 10854567. DOI: 10.3390/cells13030213.

Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.

Oh B, Chan L, Chai L Front Immunol. 2023; 13:1044946.

PMID: 36969979 PMC: 10034767. DOI: 10.3389/fimmu.2022.1044946.

References

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Trinchieri G, De Marchi M, Mayr W, Savi M, Ceppellini R . Lymphocyte antibody lymphocytolytic interaction (LALI) with special emphasis on HL-A. Transplant Proc. 1973; 5(4):1631-49. View

Morgan D, Ruscetti F, Gallo R . Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976; 193(4257):1007-8. DOI: 10.1126/science.181845. View

Baker P, Gillis S, Smith K . Monoclonal cytolytic T-cell lines. J Exp Med. 1979; 149(1):273-8. PMC: 2184737. DOI: 10.1084/jem.149.1.273. View

Perussia B, Trinchieri G, Cerottini J . Functional studies of Fc receptor-bearing human lymphocytes: effect of treatment with proteolytic enzymes. J Immunol. 1979; 123(2):681-7. View

Smith K . T-cell growth factor. Immunol Rev. 1980; 51:337-57. DOI: 10.1111/j.1600-065x.1980.tb00327.x. View

Perussia B, Trinchieri G . Inactivation of natural killer cell cytotoxic activity after interaction with target cells. J Immunol. 1981; 126(2):754-8. View

Larsson E . Mechanism of T cell activation. II. Antigen- and lectin-dependent acquisition of responsiveness to TCGF is a nonmitogenic, active response of resting T cells. J Immunol. 1981; 126(4):1323-6. View

Uchiyama T, Broder S, Waldmann T . A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981; 126(4):1393-7. View

10.

Kuribayashi K, Gillis S, Kern D, Henney C . Murine NK cell cultures: effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol. 1981; 126(6):2321-7. View

11.

Henney C, Kuribayashi K, Kern D, Gillis S . Interleukin-2 augments natural killer cell activity. Nature. 1981; 291(5813):335-8. DOI: 10.1038/291335a0. View

12.

Dennert G, Yogeeswaran G, Yamagata S . Cloned cell lines with natural killer activity. Specificity, function, and cell surface markers. J Exp Med. 1981; 153(3):545-56. PMC: 2186110. DOI: 10.1084/jem.153.3.545. View

13.

Ullberg M, Jondal M . Recycling and target binding capacity of human natural killer cells. J Exp Med. 1981; 153(3):615-28. PMC: 2186117. DOI: 10.1084/jem.153.3.615. View

14.

Abo T, Balch C . A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol. 1981; 127(3):1024-9. View

15.

Perussia B, Lebman D, Ip S, Rovera G, Trinchieri G . Terminal differentiation surface antigens of myelomonocytic cells are expressed in human promyelocytic leukemia cells (HL60) treated with chemical inducers. Blood. 1981; 58(4):836-43. View

16.

Robb R, Munck A, Smith K . T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med. 1981; 154(5):1455-74. PMC: 2186509. DOI: 10.1084/jem.154.5.1455. View

17.

Abo T, Cooper M, Balch C . Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med. 1982; 155(1):321-6. PMC: 2186573. DOI: 10.1084/jem.155.1.321. View

18.

Pross H, Baines M, Rubin P, Shragge P, Patterson M . Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol. 1981; 1(1):51-63. DOI: 10.1007/BF00915477. View

19.

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

20.

Welte K, Wang C, Mertelsmann R, Venuta S, FELDMAN S, Moore M . Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med. 1982; 156(2):454-64. PMC: 2186775. DOI: 10.1084/jem.156.2.454. View